LBS-009

About Lin BioScience

Taiwan‑based biotech developing oral small‑molecule drugs for eye disease, cancer and metabolic disorders, with multiple FDA‑designated clinical programs.

About Belite Bio

Belite Bio is a clinical-stage biotech focused on developing novel oral therapies for diseases of blindness and metabolism, built on its proprietary RBP4 (Retinol Binding Protein 4) intellectual property. Its lead candidate, Tinlarebant, is in multiple late-stage trials for Geographic Atrophy (GA) and Stargardt Disease type 1 (STGD1), having secured significant regulatory designations including Breakthrough Therapy and Orphan Drug status. The company's strategy leverages a single mechanistic platform across high-unmet-need ophthalmic indications before expanding into broader metabolic diseases like non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes.

Therapeutic Areas